Biopeople

Chairman changes chair

Chairman changes chair

29.01.2013 - Instead of renewing his contract, Bayer Healthcare AG Chairman Jörg Reinhardt (56) is seeking new opportunities.

The member of Bayer‘s Executive Council is standing for election as Director and non-executive Chairman at Novartis, and hopes to follow Daniel Vasella in the post. Board member Wolfgang Plischke will take over Reinhardt's role at Bayer. The pharma executive is returning to his roots. He began his career with Sandoz in 1981, which became part of Novartis 15 years later. In 2008, Reinhardt became COO of the Novartis Group, and in 2012 he was appointed to the Board of Lonza Group AG in Basel.

Photo: Bayer HealthCare

http://www.european-biotechnology-news.com/people/bio-people/2013-01/joerg-reinhardt.html

28.05.2013 German biosimilar specialist Formycon AG has named Dr. Carsten Brockmeyer as its new Chief Executive Officer and member of its executive board.

Brockmeyer began his industry career in 1991 at Baxter International, where he was responsible for the development and quality control of monoclonal antibodies. In 1998, he switched to HEXAL AG, where he oversaw the development of the first-ever biosimilar for epoetin alpha and for biosimilar filgrastim. A year later he became General Manager of HEXAL Biotech Forschung GmbH, which was absorbed by Sandoz Biopharmaceuticals in 2008. At Sandoz, Brockmeyer started as head of global project management. In recent years, he has advised clients through his own consulting company, Brockmeyer Biopharma. Formycons new CEO is the author of more than 100 scientific publications, and has been credited with a number of patented inventions. His acclaimed work in the field of biopharmaceuticals has been recognised by several scientific awards. 

07.05.2013 Rentschler Biotechnologie GmbH has named a seasoned industry expert as its new Chief Business Officer (CBO). Frank Ternes comes in from Boehringer Ingelheim, where he worked for 25 years, most recently as Senior Vice President of Biopharmaceutical Contract Manufacturing.

Rentschler Biotechnologie GmbH has named a seasoned industry expert as its new Chief Business Officer (CBO).

Frank Ternes comes in from Boehringer Ingelheim, where he worked for 25 years, most recently as Senior Vice President of Biopharmaceutical Contract Manufacturing. Ternes will lead the planning, development and execution of all business development, sales & marketing and project management activities for the German CRO, which began short-time work at the end of March due to “high market volatility”.

21.06.2013 The Stratified Medicine Scotland Innovation Centre will kick off in 2015 with a global life science entrepreneur at its helm. Dr David U’Prichard was selected as the first Chairman of the £20m Innovation Centre.

U’Prichard is currently president of US-based pharmaceutical and biotechnology consulting firm Druid Consulting LLC. He is also the chief scientific officer at BioMotiv LLC and a member of the corporate boards of Life Technologies Inc (now ThermoFisher Scientific), Cyclacel Inc, and Iroko Pharmaceuticals LLC. Originally from Rothesay (Scotland), but now based in Philadelphia, the new chairman has pharma-cology degrees from the University of Glasgow and the University of Kansas. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Penn-sylvania, and is an Honorary Professor at the University of Glasgow. U’Prichard has authored more than 100 publications and is a member of various editorial boards.

18.06.2013 European Bioplastics elected François de Bie to chair the lobby organisation’s new board.

Members include Maria-Giovanna Vetere (NatureWorks), Jürgen Keck (BASF), Peter Brunk (Biotec), Rainer Schweda (Braskem), and Johnny Pallot (Roquette). De Bie, who will succeed the association's former Chairman, Andy Sweetman from Innovia Films, is currently marketing manager of Dutch PLA and succinic acid producer Purac, a subsidiary of CSM N.V. Previously, he worked with Sabic Innovative Plastics and GE Plastics.

14.06.2013 Merck Millipore has granted the 2013 Alice C. Evans Award to Joan Steitz from Yale University.

Breaking new ground in research on RNA, especially in the function of small ribonucleoproteins (snRNPs) in pre-mRNA, Steitz was the first to learn that these cellular complexes (snRNPs) play a key role in processing messenger RNA by excising non-coding regions, and splicing together resulting segments.

11.06.2013 A Cancer antibody specialist BioInvent International AB (Lund) has named Michael Oredsson as its new President and CEO.

Oredsson, who will take up his post within the next six months, has  wide experience in the pharma, biotech and nutrition sectors. The current CEO of Probi AB began his carreer with Mars and Nestlé, and previously held executive positions at Bio-signal in Australia and Nutri-pharma in Norway. He was also responsible for building up Pharmacia’s OTC product division in Australia.

07.06.2013 US small molecule-drug conjugates specialist Endocyte has appointed Torsten Hoof as VP and General Manager of the company’s new European headquarters in Zug.

Hoof has extensive knowledge of product launches in the European market. The biochemist comes in from Bristol-Myers Squibb, where most recently he was VP for Global Commercialisation of the hema-tology and oncology franchise. Prior to joining BMS, he was Global Business Leader Influenza at Roche, where he led the worldwide launch of Tamiflu and several launches of HIV products in Germany.

03.06.2013 Bayer AG’s anti-infectives spin-out AiCuris GmbH and license partner Merck & Co. have been awarded the Allicense 2013 "Breakthrough Alliance Award” for their US$574m agreement in October 2012.

In the running were the five most valuable licensing agreements worldwide as nominated by analysts from Deloitte Recap. An online vote decided the winner. AiCuris CEO Prof. Dr. Helga Rübsamen-Schaeff was given the award at the end of April at the Allicense conference in San Francisco.

09.07.2013 Nicholas Michael has joined British RSSL as Senior Scientist to head up the company's protein characterisation services.

With 10 years' experience in mass spectrometry and HPLC, Nicholas has previously worked at Cancer Research and Lonza Biologics. Protein characterisation, including glycosylation profiling and impurity profiling, is one of several GMP services that RSSL offers to the pharmaceutical/bio-pharma industry.

09.07.2013 Protuduese API specialist Hovione has appointed Justin Hughey to lead the Particle Design sciences at its site in New Jersey.

The pharmacist is an acknowledged expert in the field of solubilization including the creation of amorphous solid dispersions with emphasis on Hot Melt Extrusion.  Hughey comes in from Austin-based cpmpany Enavail where he was Director of Research. His pharmaceutical development experience extends to particle engineering technologies for pulmonary delivery as well as controlled and immediate release solid oral dosage forms. 

Vorherige Seite4/8Nächste Seite

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR21.7%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 22.11.2014

Current issue

All issues